Science and Technology
Meeting the challenge of intracellular therapeutic targets
Current modalities have a limited ability to deliver certain types of therapeutic molecules to target cells. These technologies are hampered by toxicity, poor cell/tissue specificity, and reduced cellular activity due to endosomal trapping or endolysosomal processing. Vesigen’s novel therapeutic programs utilize ARMMs technology to package and safely deliver RNA, proteins, and gene-editing complexes to cells not accessible by existing delivery systems.